Rosuvastatin

ApprovedWithdrawn

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Primary Hypercholesterolaemia

Conditions

Primary Hypercholesterolaemia

Trial Timeline

Feb 1, 2002 → —

NCT ID

NCT00396240

About Rosuvastatin

Rosuvastatin is a approved stage product being developed by AstraZeneca for Primary Hypercholesterolaemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00396240. Target conditions include Primary Hypercholesterolaemia.

What happened to similar drugs?

20 of 20 similar drugs in Primary Hypercholesterolaemia were approved

Approved (20) Terminated (5) Active (0)

✅Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved

✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved

✅Duloxetine + PlaceboEli LillyApproved

✅Eszopiclone + PlaceboSumitomo PharmaApproved

✅Quetiapine extended release tablet + PlaceboAstraZenecaApproved

✅Metoprolol XL 50mg + Amlodipine 5mg + Metoprolol XL 25 mg + Amlodipine 2.5mg + Metoprolol XL 50mg + Metoprolol XL 25 mg + Amlodipine 5mgAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00160745	Phase 2	Completed	—	Sep 1, 2006	Hypercholesterolemia
NCT04846231	Phase 2	Completed	Apr 23, 2021	Jul 19, 2022	Hypercholesterolemia
NCT02561845	Pre-clinical	Withdrawn	Oct 1, 2015	Oct 1, 2015	PCI Patients
NCT02484027	Approved	UNKNOWN	Sep 1, 2015	Sep 1, 2018	Infarction, Anterior Cerebral Artery
NCT02077257	Approved	UNKNOWN	Mar 1, 2014	May 1, 2016	Acute Coronary Syndrome
NCT01837823	Phase 2	Completed	Jul 1, 2013	Apr 1, 2015	Obstructive Coronary Artery Disease
NCT01490398	Approved	Completed	Dec 1, 2011	Oct 1, 2013	Hypertension
NCT01364220	Phase 3	Terminated	Aug 1, 2010	Apr 1, 2013	Stroke
NCT00815659	Approved	Completed	Dec 1, 2008	Mar 1, 2010	Metabolic Syndrome
NCT00747149	Approved	Completed	May 1, 2008	Aug 1, 2009	Type 2 Diabetes
NCT00473655	Approved	Completed	Jan 1, 2007	Feb 1, 2009	Hypertriglyceridemia
NCT00335699	Approved	Completed	Aug 1, 2005	Jan 1, 2007	Hypercholesterolemia
NCT00184951	Phase 2	Completed	Apr 1, 2004	Jul 1, 2005	HIV Infections
NCT00240305	Phase 3	Completed	Apr 1, 2004	May 1, 2006	Metabolic Syndrome
NCT00176332	Phase 2	Completed	Mar 1, 2004	Dec 1, 2006	Heart Failure
NCT00228514	Phase 3	Completed	Feb 1, 2004	Jul 1, 2007	Rosuvastatin
NCT00240266	Phase 3	Completed	Aug 1, 2003	Dec 1, 2004	Metabolic Syndrome
NCT00241488	Phase 3	Completed	Jun 1, 2003	Feb 1, 2007	Hypercholesterolemia
NCT00660764	Pre-clinical	Completed	May 1, 2003	Apr 1, 2005	Hypercholesterolemia
NCT00239681	Phase 3	Terminated	Feb 1, 2003	Sep 1, 2008	Elevated High-sensitivity C-Reactive Protein (hsCRP)

Competing Products

20 competing products in Primary Hypercholesterolaemia

See all competitors

Product	Company	Stage	Hype Score
Unfractionated heparin	Sinopharm	Pre-clinical	33
azenosertib	Zentalis Pharmaceuticals	Phase 2	32
Latanoprost plus adjunctive glaucoma medication	Sight Sciences	Approved	25
REN001	OnKure Therapeutics	Phase 1	11
Mavodelpar + Placebo	OnKure Therapeutics	Phase 2	25
REN001	OnKure Therapeutics	Phase 2/3	20
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, Placebo	Skye Bioscience	Phase 2	25
Rituximab + Methotrexate + Cytarabine Injection	Celltrion	Phase 2	31
Rituximab, lenalidomide	Celltrion	Phase 2	42
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RIS	Chugai Pharmaceutical	Phase 3	40
CS-3150	Daiichi Sankyo	Pre-clinical	26
Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin	Daiichi Sankyo	Pre-clinical	33
Bempedoic acid 180 mg tablet	Daiichi Sankyo	Approved	43
Combination of bempedoic acid and ezetimibe	Daiichi Sankyo	Pre-clinical	33
DS-8201a + T-DM1	Daiichi Sankyo	Phase 3	44
Bempedoic acid and/or its fixed dose combination with ezetimibe	Daiichi Sankyo	Pre-clinical	18
Roxadustat + Placebo	Astellas Pharma	Phase 3	32
Enzalutamide + Exemestane	Astellas Pharma	Phase 2	35
Bocidelpar + Placebo	Astellas Pharma	Phase 2	27
Methotrexate + Ibrutinib + Temozolomide	Sun Pharmaceutical	Phase 2	31